Title: Development and Validation of a Nomogram for Predicting Endoscopic Healing in
Crohn's Disease Patients Receiving Infliximab Treatment
Version: 4 Date: 29 Apr 2025
Reviewer's report:
This was a retrospective study to develop a new nomogram for predicting outcomes in CD
patients.
- The tables are not included in the manuscript, so I am unable to complete my review.
-Please specify the assay type used for measuring IFX levels (HMSA/ELISA/RIA/POC) and
antibodies and please indicate the detectable serum IFX/ATI levels for the specific kits used.
- I do not have access to the tables, but did you assess the effect of immunomodulator use and
the duration of IFX treatment on mucosal healing (MH)?
-The discussion section is too long and would benefit from being more concise.
Title: Development and Validation of a Nomogram for Predicting Endoscopic Healing in
Crohn's Disease Patients Receiving Infliximab Treatment
Version: 4 Date: 29 Apr 2025
Reviewer's report:
This was a retrospective study to develop a new nomogram for predicting outcomes in CD
patients.
- The tables are not included in the manuscript, so I am unable to complete my review.
-Please specify the assay type used for measuring IFX levels (HMSA/ELISA/RIA/POC) and
antibodies and please indicate the detectable serum IFX/ATI levels for the specific kits used.
- I do not have access to the tables, but did you assess the effect of immunomodulator use and
the duration of IFX treatment on mucosal healing (MH)?
-The discussion section is too long and would benefit from being more concise.
Please review this paper.
user
Title: Development and Validation of a Nomogram for Predicting Endoscopic Healing in
Crohn's Disease Patients Receiving Infliximab Treatment
Version: 4 Date: 29 Apr 2025
Reviewer's report:
This was a retrospective study to develop a new nomogram for predicting outcomes in CD
patients.
- The tables are not included in the manuscript, so I am unable to complete my review.
-Please specify the assay type used for measuring IFX levels (HMSA/ELISA/RIA/POC) and
antibodies and please indicate the detectable serum IFX/ATI levels for the specific kits used.
- I do not have access to the tables, but did you assess the effect of immunomodulator use and
the duration of IFX treatment on mucosal healing (MH)?
-The discussion section is too long and would benefit from being more concise.
assistant